IDEXX Laboratories, Inc. (IDXX)

NASDAQ: IDXX · Real-Time Price · USD
528.77
+6.07 (1.16%)
At close: Jun 16, 2025, 4:00 PM
529.76
+0.99 (0.19%)
After-hours: Jun 16, 2025, 4:39 PM EDT
1.16%
Market Cap 42.52B
Revenue (ttm) 3.93B
Net Income (ttm) 894.97M
Shares Out 80.42M
EPS (ttm) 10.82
PE Ratio 48.89
Forward PE 42.35
Dividend n/a
Ex-Dividend Date n/a
Volume 352,987
Open 525.91
Previous Close 522.70
Day's Range 522.42 - 530.12
52-Week Range 356.14 - 530.73
Beta 1.55
Analysts Buy
Price Target 546.00 (+3.26%)
Earnings Date Aug 5, 2025

About IDXX

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It offers in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology, and coagulation analyzers; and SNAP rapid assays test kits. The company also provides commercial reference... [Read more]

Sector Healthcare
IPO Date Jun 21, 1991
Employees 11,000
Stock Exchange NASDAQ
Ticker Symbol IDXX
Full Company Profile

Financial Performance

In 2024, IDEXX Laboratories's revenue was $3.90 billion, an increase of 6.46% compared to the previous year's $3.66 billion. Earnings were $887.87 million, an increase of 5.07%.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for IDXX stock is "Buy." The 12-month stock price forecast is $546.0, which is an increase of 3.26% from the latest price.

Price Target
$546.0
(3.26% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Third Expansion of IDEXX's Catalyst Platform in Under a Year Delivers Critical Insights to Veterinarians Evaluating Canine Patients for Endocrine Disorders

The Catalyst ® Cortisol Test provides veterinarians with real-time critical insights when evaluating dogs for Addison's disease and Cushing's syndrome WESTBROOK, Maine , June 5, 2025 /PRNewswire/ -- I...

11 days ago - PRNewsWire

IDEXX Laboratories: Growth Remains Despite Weak Clinical Visits

IDEXX Laboratories, Inc. delivered strong Q1 FY25 results with 4.7% organic revenue and 7% adjusted EPS growth, despite weak US clinical visits. I see catalysts ahead: potential U.S. tax cuts, normali...

4 weeks ago - Seeking Alpha

IDEXX Laboratories to Present at Stifel Conference and Announces 2025 Investor Day

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Andrew Emerson, Executive Vice President and Chief Financ...

4 weeks ago - Business Wire

IDEXX Laboratories, Inc. (IDXX) Q1 2025 Earnings Conference Call Transcript

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Andrew Emerson - EVP, CFO and Treasurer Jay Mazelsky - President and CEO Conference...

6 weeks ago - Seeking Alpha

IDEXX Laboratories raises annual profit view on strong demand for its pet diagnostics

Animal diagnostics maker IDEXX Laboratories on Thursday raised its annual profit forecast after it beat Wall Street estimates for quarterly profit, as it benefited from customer retention and increase...

6 weeks ago - Reuters

IDEXX Laboratories Announces First Quarter Results

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. “IDEXX drove solid execution in the fir...

6 weeks ago - Business Wire

IDEXX Laboratories to Release 2025 First Quarter Financial Results

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 first quarter financial results for Thur...

2 months ago - Business Wire

IDEXX Laboratories: Cancer Dx Launch In March 2025; Upgrading To 'Buy'

Upgraded IDEXX to 'Buy' with a $450 price target due to oncology business expansion and share repurchase program. IDEXX's oncology market entry with Cancer Dx panel in March 2025 could drive significa...

3 months ago - Seeking Alpha

IDEXX Laboratories: A Top Dog In The Pet Care Market

The pet care industry is growing, with increasing pet ownership and spending, especially in emerging markets, providing IDEXX with significant growth opportunities. IDEXX Laboratories is the market le...

3 months ago - Seeking Alpha

IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 27, 9:05 am –...

4 months ago - Business Wire

IDEXX Laboratories And Its Real Value

IDEXX Laboratories stock has shown consistent long-term annualized growth of 24.75%. Despite a tough year with a 20% loss, IDEXX remains strong, fundamentally. IDEXX's innovative products and internat...

4 months ago - Seeking Alpha

IDEXX Laboratories: I See Pet Healthcare As An Interesting Market For The Future

IDEXX Laboratories is poised for growth in the pet healthcare market, driven by an aging pet population and strong pet-owner bonds. IDEXX's comprehensive ecosystem, including AI-driven diagnostics and...

4 months ago - Seeking Alpha

Idexx Stock, AbbVie, and Molina Buck Downward Tariff Trend. These Are Today's Top S&P 500 Performers.

Idexx Laboratories, AbbVie, and Molina Healthcare trade higher on a down day for Wall Street.

Other symbols: ABBVMOH
4 months ago - Barrons

IDEXX Laboratories, Inc. (IDXX) Q4 2024 Earnings Call Transcript

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q4 2024 Earnings Conference Call February 3, 2025 8:30 AM ET Company Participants Brian McKeon - Chief Financial Officer Andrew Emerson - Senior Vice President,...

4 months ago - Seeking Alpha

IDEXX Laboratories Stock Jumps on Testing Products Demand, Higher Prices

Shares of IDEXX Laboratories (IDXX) surged 10% to lead S&P 500 gainers Monday after the provider of veterinary healthcare products and services reported better-than-anticipated results on demand for i...

4 months ago - Investopedia

Why Is Pet Health Company IDEXX Laboratories Stock Trading Higher On Monday?

IDEXX Laboratories Inc IDXX reported fourth-quarter adjusted EPS of $2.53, up 10% year-over-year, beating the consensus of $2.40.

4 months ago - Benzinga

Animal diagnostics maker IDEXX beats quarterly estimates despite low vet visits

IDEXX Laboratories beat Wall Street estimates for fourth-quarter revenue and profit on Monday, helped by strong demand for its veterinary diagnostic services despite persistent weakness in visits to t...

4 months ago - Reuters

IDEXX Laboratories Announces Fourth Quarter and Full Year 2024 Results

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced fourth quarter and full year results. “IDEXX had a solid finis...

4 months ago - Business Wire

IDEXX Laboratories to Release 2024 Fourth Quarter and Full Year Financial Results

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 fourth quarter and full year financial r...

5 months ago - Business Wire

SR Inc Announces 2024 SBER Awards: Top Honors Go to Synopsys, Nell Triplett of Juniper Networks, and IDEXX

Sustainability Roundtable Inc. announced Synopsys, IDEXX, and Juniper Networks as winners of the 2024 SBER Awards for standout leadership in sustainability

Other symbols: SNPS
6 months ago - GlobeNewsWire

IDEXX Laboratories Announces Increase in Share Repurchase Program Authorization

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that the Company's Board of Directors authorized an increase i...

6 months ago - Business Wire

IDEXX Announces CFO Transition

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Brian McKeon has decided to retire from IDEXX effective J...

7 months ago - Business Wire

ACVIM and IDEXX Partner to Provide Free Educational Offerings for ACVIM Residents

DENVER--(BUSINESS WIRE)--The American College of Veterinary Internal Medicine (ACVIM) is excited to announce a new endorsement partnership with IDEXX Laboratories, Inc., of complimentary resident-focu...

7 months ago - Business Wire

IDEXX Laboratories Q3: Weak End-Market Demand Continues

I reiterate a 'Sell' rating on IDEXX due to weak U.S. clinical visits and demand, with a one-year price target of $400 per share. IDEXX's Q3 results showed a 2.1% decline in same-store clinical visits...

7 months ago - Seeking Alpha

IDEXX Laboratories, Inc. (IDXX) Q3 2024 Earnings Call Transcript

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Brian McKeon - CFO Jay Mazelsky - President and CEO Conference Call Participan...

8 months ago - Seeking Alpha